Cargando…
THU093 Pituitary Enlargement And Hypopituitarism In Patients Treated With Immune Checkpoint Inhibitors: Two Sides Of The Same Coin?
Disclosure: S. Menotti: None. S. Chiloiro: None. A. Giampietro: None. A. Bianchi: None. F. Angelini: None. T. Tartaglione: None. G. Antonini Cappellini: None. F. De Galitiis: None. E. Rossi: None. G. Schinzari: None. A. Scoppola: None. A. Pontecorvi: None. L. De Marinis: None. M. Fleseriu: None. Int...
Autores principales: | Menotti, Sara, Chiloiro, Sabrina, Giampietro, Antonella, Bianchi, Antonio, Angelini, Flavia, Tartaglione, Tommaso, Antonini Cappellini, Gian Carlo, De Galitiis, Federica, Rossi, Ernesto, Schinzari, Giovanni, Scoppola, Alessandro, Pontecorvi, Alfredo, De Marinis, Laura, Fleseriu, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554223/ http://dx.doi.org/10.1210/jendso/bvad114.1173 |
Ejemplares similares
-
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?
por: Chiloiro, Sabrina, et al.
Publicado: (2023) -
THU050 The Role Of The GH Receptor Polymorphism As Prognostic Factor Of Vertebral Fractures In Acromegaly Patients Resistant To First Generation SSAs And Treated With GH Receptor Antagonist Or Second Generation Somatostatin Ligand
por: Costanza, Flavia, et al.
Publicado: (2023) -
MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020) -
SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019) -
THU055 The Acro-TIME Score: A New Clinical, Pathological And Immune Integrative Approach To Early Identify Acromegaly Patients Resistant To Treatment With First Generation Somatostatin Ligands
por: Chiloiro, Sabrina, et al.
Publicado: (2023)